{
    "root": "33da187f-72d1-daa5-e063-6394a90a66b1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Horizant",
    "value": "20250428",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "DIBASIC CALCIUM PHOSPHATE DIHYDRATE",
            "code": "O7TSZ97GEP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2",
            "drugbank_id": "https://go.drugbank.com/drugs/DB13038"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "GABAPENTIN ENACARBIL",
            "code": "75OCL1SPBQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_68840"
        }
    ],
    "indications": {
        "text": "horizant indicated : treatment moderate-to-severe primary restless legs syndrome ( rls ) adults . ( 1.1 ) management postherpetic neuralgia ( phn ) adults . ( 1.2 )",
        "doid_entities": [
            {
                "text": "restless legs syndrome (DOID:0050425)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050425"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe primary restless",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_468726"
            }
        ]
    },
    "contraindications": {
        "text": "instruct patients swallow tablets whole cut , crush , chew tablets . take food . ( 2.1 ) rls : 600 mg daily taken 5 pm . ( 2.2 ) dose 1,200 mg daily provided additional benefit compared 600-mg dose , caused increase . ( 2.2 ) dose taken recommended time , next dose taken following day prescribed . ( 2.2 ) phn : starting dose 600 mg morning 3 days , increase 600 mg twice daily beginning day 4 . ( 2.3 ) daily dose greater 1,200 mg provided additional benefit . ( 2.3 ) dose taken recommended time , skip dose , next dose taken time next scheduled dose . ( 2.3 ) patients renal impairment : doses horizant must adjusted accordance renal function . ( 2.4 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "horizant extended-release tablets containing 300 mg gabapentin enacarbil white off-white , occasional black/grey spots , oval-shaped tablets debossed `` gs tf7 `` . horizant extended-release tablets containing 600 mg gabapentin enacarbil white off-white , occasional black/grey spots , oval-shaped tablets debossed `` gs lfg `` . supplied follows : 300 mg : ndc 53451-0103-1 : bottles 30 600 mg : ndc 53451-0101-1 : bottles 30",
    "adverseReactions": "none .",
    "indications_original": "HORIZANT is indicated for: treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. ( 1.1 ) management of postherpetic neuralgia (PHN) in adults. ( 1.2 )",
    "contraindications_original": "Instruct patients to swallow tablets whole and not to cut, crush, or chew tablets. Take with food. ( 2.1 ) RLS: 600 mg once daily taken at about 5 PM. ( 2.2 ) A dose of 1,200 mg once daily provided no additional benefit compared with the 600-mg dose, but caused an increase in adverse reactions. ( 2.2 ) If the dose is not taken at the recommended time, the next dose should be taken the following day as prescribed. ( 2.2 ) PHN: The starting dose is 600 mg in the morning for 3 days, then increase to 600 mg twice daily beginning on day 4. ( 2.3 ) A daily dose greater than 1,200 mg provided no additional benefit. ( 2.3 ) If the dose is not taken at the recommended time, skip this dose, and the next dose should be taken at the time of next scheduled dose. ( 2.3 ) Patients with renal impairment: Doses of HORIZANT must be adjusted in accordance with renal function. (2.4)",
    "warningsAndPrecautions_original": "HORIZANT Extended-Release Tablets containing 300 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with \"GS TF7\".\n                  HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with \"GS LFG\". They are supplied as follows:\n                  300 mg: NDC 53451-0103-1: Bottles of 30 \n    600 mg: NDC 53451-0101-1: Bottles of 30",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Horizant",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        }
    ]
}